MedTrace Logo

Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat

NCT06569589 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-06-06

No results posted yet for this study

Summary

The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

23NaMRI Scan

23NaMRI, a non-invasive detection and quantification of hidden tissue Na+ stores in humans.

DIETARY_SUPPLEMENT

Potassium Chloride (KCl)

K+ supplementation intervention is given participants as part of their standard care. In this trial the K+ supplementation dosage is standardized and adjusted based on blood K+ level

Sponsors & Collaborators

  • Changi General Hospital

    collaborator OTHER

  • Singapore General Hospital

    collaborator OTHER

  • Sengkang General Hospital

    collaborator OTHER

  • Jens Titze

    lead OTHER

Principal Investigators

  • Jens Titze, MD · Duke-NUS Graduate Medical School

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-27
Primary Completion
2026-03-31
Completion
2026-08-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06569589 on ClinicalTrials.gov